TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

TAVR specialists come together to explore new data, patient selection and much more
Care teams have a lot to consider when choosing the right treatment for patients with severe aortic stenosis. Two cardiologists and a veteran cardiothoracic surgeon are taking part in a new webinar focused on that very topic.
Heart surgeons perform world’s first robotic TAVR explant and aortic valve replacement
The patient, 67, presented with a failing TAVR valve and a leaky mitral valve. She had undergone TAVR four years prior, but premature structural valve degeneration made a full replacement necessary. Surgeons ultimately removed the TAVR valve in addition to replacing her aortic and mitral valves—all with the help of advanced robotics.
Real-world data favor SAVR over TAVR when younger patients need aortic valve replacement
Researchers in Italy tracked data from more than 7,000 patients who underwent AVR between the ages of 65 and 80. TAVR was associated with a significantly higher long-term risk of mortality.
Heart patients benefit when cardiologists follow a standardized TAVR protocol
Using a standardized approach, including the cusp overlap technique, is associated with improved patient outcomes when implanting Medtronic's self-expanding TAVR valves. Researchers tracked data from more than 600 patients treated all over the world, presenting their findings in JSCAI.
How anticoagulants may impact a patient’s risk of gastrointestinal bleeding after TAVR
Researchers tracked the rates of major gastrointestinal bleeding in patients with AFib randomized to receive edoxaban or a vitamin K antagonist after a successful TAVR procedure.

PHOTO GALLERY: Highlights from ACC.24 in Atlanta

ACC.24, the American College of Cardiology's annual meeting in Atlanta, featured the latest in cardiovascular research and technologies. Representatives from Cardiovascular Business were there in person to take in the excitement.

Video of Howard Herrmann, MD, explaining the details of the SMART trial that looked at TAVR in small annulus and found self-expanding TAVR valves work better in these patients than balloon-expanding TAVR.

Cardiologist highlights key takeaways from SMART trial, which looked at TAVR in small annulus patients

Howard C. Herrmann, MD, principal investigator of the SMART trial, discussed his team's research on self-expanding vs. balloon-expandable TAVR valves in patients with small annuli.

doctor examines patient data on their tablet

TAVR, SAVR both linked to low reintervention rates after five years

While most TAVR-related reinterventions occurred in the first year after treatment, most SAVR-related reinterventions occurred in years two through five. The team's full analysis is available in JACC: Cardiovascular Interventions.

Newsweek ranked the 50 best heart hospitals in the world

ACC.24: TAVR linked to lower 1-year mortality, stroke rates than SAVR in low-risk patients

TAVR is noninferior to SAVR when treating low-risk patients, according to new data presented at ACC.24. In fact, it is associated with multiple benefits over surgery.

ACC.24: Self-expanding Evolut valves offer superior performance for TAVR patients with small annuli

The SMART trial included one-year data from TAVR patients randomized to receive either a self-expanding Evolut valve or a balloon-expandable Sapien 3 valve. All patients presented with symptomatic severe aortic stenosis and a small aortic annulus. A whopping 87% of participants were women.

Moderate prosthesis-patient mismatch after SAVR linked to worse long-term outcomes

The long-term impact of moderate PPM remains unclear. To learn more, researchers explored dozens of different studies from over the years, sharing their work in the Journal of the American Heart Association.

New risk score helps cardiologists predict when TAVR patients may require dialysis

Patients who need renal replacement therapy after TAVR are much less likely to survive. Researchers hope their new risk score can help care teams prepare ahead of time for this rare, but potentially fatal complication.

Medtronic has received U.S. Food and Drug Administration (FDA) approval for its Evolut FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis.

FDA approves Medtronic’s next-generation TAVR system with new frame design

The Evolut FX+ TAVR system includes an updated diamond-shaped frame, which was made four times larger than previous models to offer improved coronary access. It was also designed to provide more space for operators to guide and maneuver the catheter during procedures.

TAVR

TAVR specialists come together to explore new data, patient selection and much more

Heart surgeons perform world’s first robotic TAVR explant and aortic valve replacement

Real-world data favor SAVR over TAVR when younger patients need aortic valve replacement

Heart patients benefit when cardiologists follow a standardized TAVR protocol

How anticoagulants may impact a patient’s risk of gastrointestinal bleeding after TAVR